Masimo Corporation (NASDAQ:MASI) Given Consensus Recommendation of “Hold” by Analysts

Shares of Masimo Corporation (NASDAQ:MASI) have been assigned a consensus recommendation of “Hold” from the eight research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $188.40.

A number of research analysts have recently issued reports on MASI shares. Wall Street Zen upgraded shares of Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Piper Sandler raised their price target on Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 6th. Wells Fargo & Company reduced their price objective on Masimo from $190.00 to $187.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Zacks Research cut Masimo from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a report on Wednesday, October 8th.

Masimo Stock Down 1.7%

Shares of NASDAQ MASI opened at $143.96 on Friday. Masimo has a 52-week low of $133.70 and a 52-week high of $194.88. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14. The business has a fifty day moving average of $145.71 and a two-hundred day moving average of $152.58. The stock has a market cap of $7.73 billion, a PE ratio of -16.90 and a beta of 1.28.

Masimo (NASDAQ:MASI) last announced its earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share (EPS) for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The business had revenue of $617.00 million during the quarter. As a group, equities research analysts expect that Masimo will post 4.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Masimo

Large investors have recently modified their holdings of the stock. Twin Tree Management LP bought a new stake in shares of Masimo during the first quarter valued at approximately $29,000. MAI Capital Management lifted its holdings in Masimo by 176.7% during the 2nd quarter. MAI Capital Management now owns 202 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 129 shares in the last quarter. Hilltop National Bank bought a new position in Masimo in the 2nd quarter valued at $37,000. Smartleaf Asset Management LLC increased its stake in shares of Masimo by 80.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 306 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 136 shares during the period. Finally, Advisory Services Network LLC bought a new stake in shares of Masimo during the third quarter worth $46,000. 85.96% of the stock is currently owned by institutional investors and hedge funds.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.